Autor: |
Maria Luisa Agüera, Alejandro Martin-Malo, Maria Antonia Alvarez-Lara, Victoria Eugenia Garcia-Montemayor, Petra Canton, Sagrario Soriano, Pedro Aljama |
Jazyk: |
angličtina |
Rok vydání: |
2015 |
Předmět: |
|
Zdroj: |
PLoS ONE, Vol 10, Iss 8, p e0135967 (2015) |
Druh dokumentu: |
article |
ISSN: |
1932-6203 |
DOI: |
10.1371/journal.pone.0135967 |
Popis: |
The appropriate use of intravenous (i.v.) iron is essential to minimise the requirements for erythropoiesis-stimulating agents (ESAs). The clinical efficacy of generic i.v. iron compared to the original formulation is controversial. We evaluated the changes that were induced after switching from a generic i.v. iron to an original formulation in a stable, prevalent haemodialysis (HD) population.A total of 342 patients were included, and the follow-up period was 56 weeks for each formulation. Anaemia parameters and doses of ESA and i.v. iron were prospectively recorded before and after the switch from generic to original i.v. iron.To maintain the same haemoglobin (Hb) levels after switching from the generic to the original formulation, the requirements for i.v. iron doses were reduced by 34.3% (from 52.8±33.9 to 34.7±31.8 mg/week, p |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|